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Abstract 
Digital image analysis is becoming central to the quantitative evaluation of tissue 
biomarkers for discovery, diagnosis and therapeutic selection for the delivery of precision 
medicine.  In this study, automated digital image analysis using a new purpose-built 
software platform (QuPath) is applied to a cohort of 293 breast cancer patients to score five 
biomarkers in tissue microarrays: ER, PR, HER2, Ki67 and p53.  This software is able to 
measure IHC expression following fully automated tumor recognition in the same IHC 
stained tissue section, as part of a rapid workflow to ensure objectivity and accelerate 
biomarker analysis.  The digital scores produced by QuPath were compared with manual 
scores by a pathologist and shown to have a good level of concordance in all cases (Cohen’s 
κ>0.6), and almost perfect agreement for the clinically relevant biomarkers ER, PR and HER2 
(κ>0.86).  To assess prognostic value, cutoff thresholds could be applied to both manual 
and automated scores using the QuPath software, and survival analysis performed for 5-
year overall survival.  Digital image analysis was shown to be capable of replicating the 
statistically significant stratification of patients achieved using manual scoring across all 
biomarkers (p<0.01, log-rank test).  Furthermore, the image analysis scores were shown to 
consistently lead to statistical significance across a wide range of potential cutoff thresholds, 
indicating the robustness of the method, and identify subpopulations of cases exhibiting 
different expression patterns within the p53 and Ki67 datasets that warrant further 
investigation.  These findings have demonstrated QuPath’s suitability for fast, reproducible, 
high-throughput tissue microarray analysis across a range of important biomarkers.  This 
was achieved using our tumor recognition algorithms for IHC stained sections, trained 
interactively without the need for any additional tumor recognition markers, e.g. 
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cytokeratin, to obtain greater insight into the relationship between biomarker expression 
and clinical outcome applicable to a range of cancer types. 
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The microscopic analysis of tissue samples continues to be the mainstay of diagnosis, 
grading and therapeutic decision-making in solid cancers, also for precision medicine and 
targeted therapy.  In this context, the diagnostic test therefore acts as a reliable companion 
to the selection of therapy for an individual patient. Indeed, in solid cancers, tissue or 
cellular samples are the core of predictive pathology or personalized medicine1.    
 
Tissue samples can be used in multiple manners to achieve a diagnostic goal2. They serve to 
identify mutations or other genomic anomalies from extracted nucleic acids by low-
throughput PCR or next generation sequencing, by labelling sequences in vitro using FISH or 
DISH, RNA in situ detection, or immunohistochemical (IHC) detection of proteins.  The latter 
probably presents the most widely used, cost-effective and practical solution for biomarker 
evaluation in primary diagnostics, and is used extensively in research for the rapid screening 
of candidate biomarkers in multiplex platforms such as tissue microarrays (TMAs). 
 
Despite the existence of robust guidelines for optimization3,4, on its own IHC is limited by 
the subjectivity associated with a) the characterization of the appropriate tumor areas to 
analyze within a complex tissue section; and b) the visual interpretation of the expression 
patterns and intensities in tumor cells and surrounding tissues.  Numerous studies have 
shown poor inter-laboratory, inter-observer and intra-observer reproducibility in the 
assessment of IHC expression patterns of tissue5,6.  This variability is slowing the progress of 
biomarker discovery and delivery of precision medicine.   
 
Automated digital image analysis (DIA) has the potential to provide the objectivity, reliability 
and speed required to radically transform tissue biomarker research, discovery and routine 
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delivery.  It is only recently, however, that the scanning technology, image processing and 
image understanding algorithms are aligning to allow solutions to be developed with 
genuine impact7.  
 
This paper demonstrates the application and evaluation of a new, comprehensive digital 
pathology image analysis platform developed in-house at Queen’s University Belfast: 
QuPath.  The platform allows a) the accurate recognition of tumor and non-tumor cells 
within whole or TMA sections using automated digital algorithms, and b) reproducible IHC 
scoring of relevant biomarkers, which provides an alternative to traditional, subjective 
manual scoring.  Hereby we demonstrate QuPath’s ability to achieve robust biomarker 
scoring to support high-throughput studies, and to provide additional, quantitative data that 
can offer new insights into biomarker interpretation. The QuPath software presented here 
represents an advanced platform for algorithm development, with the ability to accelerate 
tissue research and provide the tools to link discovery with diagnostics.  
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Materials and Methods 
Study design 
Image analysis was applied to score the clinically important biomarkers estrogen receptor 
(ER), progesterone receptor (PR) and HER2, in addition to Ki67 and p53, in TMAs for a 
cohort of 293 female patients with de novo breast cancer who were diagnosed and received 
treatment in Northern Ireland.  Tissue from each patient was sampled in triplicate from 
different regions of the tumor, giving rise to a total of 9 TMA blocks each containing 90-100 
tissue cores.  Full clinical and pathological follow-up was available for each patient, and full 
details regarding the cohort have been published previously8.  Of note, 169 cases were 
Grade 3 (58%), 119 cases Grade 2 (41%) and 5 cases Grade 1 (2%), while at time of diagnosis 
175 tumors were ER +ve (60%), 115 ER -ve (39%) and 3 had unknown ER status (1%).  All 
patients received anthracycline-based chemotherapy, with or without radiotherapy8. 
 
Immunohistochemistry 
All IHC was performed in a hybrid laboratory (Northern Ireland Molecular Pathology 
Laboratory) that has UK Clinical Pathology Accreditation, using established protocols 
described in detail elsewhere8.  The antibodies used were as follows: Anti-ER (clone 6F11 
mouse monoclonal antibody; Leica); Anti-PR (clone PgR 636 mouse monoclonal antibody; 
Dako); Anti-HER2 (clone CB11 mouse monoclonal antibody; Leica); Anti-p53 (clone DO-7 
mouse monoclonal antibody; Dako, Cambridgeshire, UK).  In the case of Ki67, the original 
dataset was stained with NCL-Ki67-MM1 antibody on a Leica staining platform with a 
polymer based detection system.  Because of the recognized variation in Ki67 antibodies, 
and in particular their suitability for image analysis9, additional tissue sections were also cut 
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and stained with Confirm anti-Ki67 (clone 30-9) antibody on a Ventana platform with an 
Optiview detection kit for comparison. 
 
Manual scoring 
All biomarkers in this dataset were scored manually by a pathologist as described 
previously8, and the pathologist also selected appropriate clinical cutoff thresholds that 
should be applied to these scores following standard guidelines in the literature8. This 
allowed us to obtain a binary ‘clinical score’ variable distinguishing between positive and 
negative cases, which is not necessarily the modus operandi in clinical practice for some of 
these biomarkers but allowed a clear-cut comparison of the results. Briefly, ER and PR were 
evaluated using the Allred scoring method, giving scores in the range 0-8, where a score ≥ 3 
was considered positive provided the proportion score was at least 2.  Ki67 was evaluated 
using visual estimates of the percentage of positive staining tumor cells (range 0-100%), 
where ≥ 15% was considered positive.  HER2 was scored in IHC according to current USA/UK 
guidelines11,12 taking into consideration membranous staining only; cases scored as 0 and 1+ 
were considered negative, while 3+ was considered positive; equivocal cases (2+) were 
further subjected to DDISH analysis to identify amplification and categorized as positive or 
negative accordingly.  p53 was assessed by calculating H-scores (range 0-300)13,14 based 
upon nuclear staining.  For p53 only, two cutoff thresholds (H-scores of 6 and 160) were 
required to separate extreme expression (both positive and negative) from the intermediate 
‘wild-type’ phenotype.  For the other biomarkers, a single cutoff was selected to separate 
strong/positive from weak/negative expression. Manual Ki67 scores were available for the 
MM1 antibody only. 
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Digital image analysis 
All image analysis was performed using QuPath, which is a flexible software platform 
suitable for a range of digital pathology applications.  In this study, the primary image 
analysis workflow comprised stain estimation, TMA dearraying, cell segmentation, feature 
computation, and tumor cell identification with intensity classification (see Supplementary 
Figure 1).  Application of this workflow resulted in both fine-grained cell-by-cell analysis and 
overall summary scores of biomarker expression for each TMA core.  Dearraying consisted 
of an automated first step of core detection and grid assignment, followed by a manual 
quality assurance check during which the grid could be manually refined and cores removed 
if considered unsuitable for analysis (e.g. because of insufficient tissue or dominant 
artifacts).   
 
Cells are identified within QuPath using an custom, unsupervised algorithm based on stain 
separation using color deconvolution14, followed by a sequence of image processing 
operations used to identify potential nucleus fragments either in the hematoxylin channel 
or from the sum of optical density values, depending upon stain characteristics.  
Morphological operations are then applied to merge and split fragments to identify 
individual nuclei.  Each detected nucleus is expanded to give an approximation of the full 
cell area, constrained by distance and the proximity of neighboring nuclei, or by the 
presence of membrane staining in the case of HER2.  A list of 103 (ER, PR, Ki67, p53) or 115 
(HER2) features derived from cell morphometry and intensity measurements are then 
calculated for each cell (Supplementary Table 1).  A random trees classifier15 is trained 
separately for each IHC biomarker using these features by having an experienced user 
annotate regions in a subset of the TMA cores across up to three slides, with interactive 
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feedback on classification performance provided during training in the form of markup 
images.  This limit of three sides was not imposed by QuPath, but was applied to ensure that 
the majority of the TMA cores used in the analysis were ‘unseen’ during training – as would 
normally be the case in high-throughput studies.   
 
Cells were further subclassified according to staining intensity by applying manually-
selected thresholds to mean DAB optical density values determined by color 
deconvolution14 from the nuclear compartment (ER, PR, Ki67, p53) or membrane (HER2) of 
each cell.  Cells close to the border of the core were removed by an iterative algorithm, 
which first calculated the convex hull for all cell centroids and then removed cells occurring 
on the boundary.  This reduced the risk of artefacts impacting the final scores by excluding a 
thin layer of cells found at the outer edge of the tissue, while retaining the cells in the 
center. 
 
Whole slide images were hosted remotely by PathXL (Belfast, UK), while analysis was 
performed locally on a desktop computer using a custom integration with PathXL’s API.  
After an initial interactive pre-analysis used to identify TMA cores and train up the tumor 
cell classification, scripts were generated for each biomarker to automate the analysis 
across the full dataset. 
 
Generation of summary scores 
TMA cores identified as containing fewer than 100 tumor cells were excluded as unsuitable 
for scoring by DIA.  After application of this selection criterion, the image analysis workflow 
resulted in 3911 tissue cores scored across all biomarkers, each containing an average of 
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3440 cells, of which 50.1% were classified as tumor cells.  For each core, the tumor cell 
counts were combined into summary measurements incorporating information about DAB 
staining intensity, including the H-score (range 0-300), Allred score (range 0-8) and the 
percentage of cells staining positive (0-100%).  For consistency, the H-score was used as the 
primary image analysis output for ER, PR and p53, while the percentage of positive tumor 
cells was used for Ki67 – equivalent to the standard Ki67 labelling index16.  To more closely 
match clinical guidelines for HER2 scoring17,18 a modified H-score was calculated for HER2 as 
follows: cores having at least 10% tumor cells with strongly positive membranous staining 
were automatically assigned the maximum value (300) and cores exhibiting less than 10% 
moderate staining were assigned the minimum value (0), while all other cases were 
considered equivocal and the original H-score was retained.  Where multiple summary 
measurements were available for a patient for each biomarker, the median was used as 
representative for that patient, so that each patient had at most one score per biomarker. 
 
Statistical analysis 
Pearson’s and Spearman’s correlation coefficients were used to examine the relationship 
between the ‘raw’ image analysis results and the pathologist’s manual scores.  Further 
comparisons were then performed after applying cutoff thresholds to both sets of scores 
and considering 5-year overall survival.  In the case of the visual assessment, the pathologist 
who performed the scoring selected clinically relevant cutoff thresholds, as described 
above. For automated image analysis, a wider range of potential cutoff values was possible 
due to the more continuous nature of the scoring methodologies used.  Therefore, several 
different methods were explored: (a) median (or tertiles, in the case of p53), (b) ‘minimized 
p-value’, based upon a log-rank test using overall survival and considering all possible 
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thresholds, excluding the top and bottom 10%, and (c) manual, in which a biologically 
plausible threshold was chosen that divided the patients into groups of roughly equal size to 
those previously identified by the pathologist to achieve comparability – while restricted to 
rounded values to reduce overfitting artifacts.  It is important to note that method (b) 
inherently involved multiple testing, which leads to p-values which are too small and cutoffs 
that potentially lack clinical meaning19–21; consequently, we also report adjusted p-values to 
aid interpretation of the results20.  For p53, which required two cutoffs, method (b) was 
adapted to return one cutoff above and one cutoff below the median, and the log-rank test 
was performed comparing extreme positive and negative versus intermediate scores. 
 
Analysis was performed and plots were created using QuPath’s built-in data exploration 
tools, and verified using R version 3.3.122 (with the ‘survival’ package23) or MATLAB (R2016a, 
The MathWorks, Inc., Natick, Massachusetts, United States) to confirm accuracy. 
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Results 
Tumor cell classification 
For all the biomarkers under investigation here, conventional scoring requires selective 
analysis only within the tumor cell population.  For this reason, reliably and automatically 
identifying tumor cells is an essential component of any high-throughput image analysis of 
this type.  To facilitate this, QuPath enables interactive training of cell classification, after 
which the classifier can be saved and run over multiple slides, and the results visualized via 
color-coded markup images.  Representative examples of these markup images are shown 
in Figure 1 and in Supplementary Figures 2-4. 
 
Concordance between pathologist and image analysis scoring 
The correlations between DIA and pathologist biomarker scores are summarized in Table 1. 
A high level of correlation between manual and DIA scores is demonstrated in all cases.  The 
area under the Receiver Operating Characteristic curve (AUC) provides a measure of how 
the DIA scores may be thresholded to align to the pathologist’s clinical (binary) score, where 
values above 0.949 indicate almost perfect agreement for the three clinical biomarkers ER, 
PR and HER2.  Correlation remained high using both antibodies for Ki67, despite the 
pathologist’s scoring being based solely on the MM1 stained images.  Correlation between 
DIA scores using each antibody against Ki67 was also high (PCC = 0.794, rho = 0.778). 
 
Survival analysis 
When assessing the performance of any new approach to scoring IHC biomarkers, it is 
inadequate to use agreement with manual scoring as the only ‘gold standard’ due to the 
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high inter- and intra-observer variability between pathologists24,25.  Consequently, we 
incorporated survival analysis after stratifying patients using the cutoff methods described 
above to ascertain the extent to which DIA and manual scores are each able to 
independently identify a statistically significant stratification of patients for each biomarker.  
The results looking at 5-year overall survival are shown in Table 2, along with Kaplan Meier 
curves using manual cutoffs in Figure 2 (comparable Kaplan Meier curves based upon the 
pathologist’s scoring are given in Supplementary Figure 5).  While the analysis was applied 
to the same cohort, slightly lower numbers of patients are represented for the DIA scoring 
due to differences in core selection, e.g. through the exclusion of small or folded tissue 
sections from DIA, or the automated rejection of cores containing fewer than 100 detected 
tumor cells.  For all biomarkers considered, it was possible to achieve a stratification of 
patients with a similar or improved statistical significance (log-rank test, p-value < 0.05) 
using DIA when compared with manual scoring using all of the cutoff determination 
methods that were applied, with the exception of the median cutoff for HER2 – which did 
not provide a result, since more than half of the cases had the minimum score of 0.  This is 
consistent with a prevalence of HER2 overexpression in breast cancers of 15-20%, which is 
not taken into consideration when using a 50% cutoff17.  However, in the case of Ki67 
statistical significance was only seen with DIA when the Confirm antibody was used, but not 
MM1.  This is consistent with reports suggesting that Ki67 is particularly challenging for DIA, 
with a dependency upon the specific antibody9,26. 
 
Robustness of cutoff thresholds 
Table 2 demonstrates that a highly significant association with survival can be obtained 
using DIA in almost all cases, even when using quite different methods of cutoff selection 
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that result in very different cutoff values.  For example, the p-values obtained using 
thresholds of 5 and 126.5 were almost identical when applied to ER (both < 0.002), despite 
the fact that changing the cutoff resulted in 43 patients (16%) being assigned to different 
groups. 
 
To further explore the impact of cutoff selection upon the identified associations with 
survival, we generated plots showing the distribution of log-rank p-values for all possible 
thresholds for the different biomarkers (Figure 3). The plots for ER, PR and HER2 all show a 
wide range of values below the conventional threshold of 0.05 taken to denote statistical 
significance. For ER, this implies that any cutoff between 1 and 265 (a range encompassing 
the scores of 181 patients with 22 observed events) would yield a p-value below the 0.05 
significance threshold. Similarly, any cutoff between 1 and 237 (140 patients and 16 
observed events) would yield a significant difference for PR H-scores, and any cutoff 
between 1 and 150 (8 patients and 2 observed events) would be significant for HER2 (Figure 
3, top 3 panels). 
 
Figure 3 also highlights the stark difference in Ki67 scores using each antibody. In the case of 
MM1, no single cutoff can be used to identify statistically significant differences (i.e. the 
curve never dips below the 0.05 line), and indeed the curve fluctuates quite widely – 
implying limited prognostic value. However, the analysis using the Confirm antibody shows 
a pronounced dip precisely in the range expected based upon proposed Ki67 cutoffs of 
clinical relevance24, so that a significant difference in overall survival would be seen by 
applying any cutoff between 7 and 26 (a range encompassing 98 patients and 13 observed 
events). 
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Alternative scoring methods 
Having demonstrated the ability of DIA to robustly score all the biomarkers within this 
study, we next wanted to examine the importance of tumor recognition and the impact of 
different DIA scoring approaches and methodologies.  To do this, we took advantage of the 
fact that QuPath generates data on every individual cell that it detects, and this information 
can easily be recombined to produce alternative scores.  To assess the importance of tumor 
recognition, we created a set of H-scores where every cell – irrespective of tumor 
classification – contributed to the result. Furthermore, for ER, PR and p53 we calculated 
Allred scores based on tumor cells to provide an alternative to the H-score used otherwise27.  
In all cases, clinically relevant cutoffs were determined automatically by selecting the 
integer threshold that maximized Youden’s J statistic, comparing DIA scores with the 
pathologist’s clinical score for each patient. This maximized the sum of the sensitivity and 
specificity, and ensured that all cutoffs were in a clinically meaningful range. 
 
These results are summarized in Table 3.  When comparing thresholded manual scores with 
H-scores generated by DIA using tumor identification, near perfect agreement is seen for 
ER, PR and HER2 (Cohen’s kappa > 0.86 in all cases), and good agreement for Ki67 and p53 
(kappa > 0.6).  Lower agreement is generally seen for all other methods of scoring all 
biomarkers, in addition to lower sensitivity, specificity and accuracy in most cases.  
However, lower agreement with the pathologist’s scoring does not always translate into a 
loss of statistical significance when associating the results with survival.  Interestingly, a 
significant association with overall survival is seen when applying the H-score to all cells (i.e. 
without tumor recognition) in most cases – indicating that, for at least some IHC biomarkers 
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that are conventionally scored only within the tumor cell population, accurate tumor 
recognition is not a necessary prerequisite for identifying associations within a sufficiently 
large cohort for a TMA study, where a measure of tumor identification is already 
incorporated in the region selection applied when constructing the TMAs.  Nevertheless, in 
most cases the inclusion of a digital tumor identification step has a substantial positive 
impact upon the quality of the results, and improved agreement with the pathologist’s 
scores.  Furthermore, the range of cutoffs that may be applied to yield a significant 
stratification was always substantially larger whenever tumor recognition was applied – 
indicating its role in improving the robustness of the results, and increasing the likelihood 
that any cutoff used would generalize well to new data (Supplementary Table 2).  Finally, it 
should be kept in mind that biomarkers exist for which expression within the stromal cells is 
of equal or greater importance to the expression within the tumor cells, and also that the 
automatic exclusion of cores containing fewer than 100 tumor cells is only possible 
whenever tumor identification is done; without this, a more time-consuming manual quality 
assurance would be required to remove cores lacking in sufficient tumor cells for reliable 
analysis. 
 
In addition to the value of tumor recognition, Table 3 also shows the value of a DIA scoring 
mechanism with a wide dynamic range.  Use of the H-score (range 0-300) consistently 
outperformed the Allred score (0-8), both in terms of agreement with the pathologist’s 
cutoffs and in associations with survival. 
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Application of multiple cutoffs to p53 
Manual scoring of p53 within this dataset made use of two cutoffs, as it was previously 
shown by our group that this was important to distinguish extreme positive and extreme 
negative from moderate staining patterns8.  Consequently, DIA scores were also generated 
here with two cutoffs.  Nevertheless, the continuous nature of the H-score provided by DIA 
makes it amenable to alternative approaches to cutoff selection, which may be particularly 
valuable when biologically-derived cutoffs are not available.  One intuitive method is to 
consider ‘valleys’ present within p-value plots such as those shown in Figure 3 as being 
suggestive of where appropriate cutoff thresholds may lie.  Applying this in the case of p53, 
the plot actually suggests two potential cutoffs to separate weak from moderate staining: at 
around H-scores of 15 and 50.  Applying each of these independently leads to a significant 
stratification when comparing weak staining with moderate (p values of 0.00038 and 0.0033 
respectively; strong staining with an H-score > 150 omitted).  However, using all suggested 
cutoffs (15, 50 and 150) it is possible to identify four distinct patient subgroups according to 
different levels of staining: negative (< 15; 49 patients), weak (≥ 15, < 50; 63 patients), 
moderate (≥ 50, < 150; 67 patients) and strong (≥ 150; 101 patients).  The negative subgroup 
has the worst prognosis, with a statistically significant difference between this and the weak 
subgroup (p = 0.0398).  The separation between negative and moderate is highly significant 
(p = 0.0002), while the separation between weak and moderate remains significant (p = 
0.049), as does the separation between moderate and strong (p = 0.0057).  To our 
knowledge, this additional separation between negative/weak subpopulations was not 
previously reported, and not identified using the manual scoring by a pathologist8.  This 
indicates another clear benefit in the continuous, reproducible scoring possible using DIA, 
where new expression phenotypes that may not be distinguished reproducibly by the naked 
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eye can be identified using quantitative characterization of biomarkers (Figure 4).  Example 
images are provided in Supplementary Figure 8. 
 
Reevaluation of p53 and Ki67 according to ER status 
While exploration of different cutoff values for categorizing scores produced by DIA, as 
described above, may provide additional insights regarding the staining of individual 
biomarkers in isolation, there is a risk of spurious findings by allowing survival information 
to inform cutoff choices due to the known problem of multiple testing20 – particularly where 
a narrow range of cutoff values leads to a statistically significant result.  Rather than 
applying numerous cutoffs to a full cohort, a clearer picture may emerge by considering 
patients separately according to different molecular subtypes. 
 
To explore this, we repeated the survival analysis of p53 and Ki67 using DIA scores after 
separating patients according to ER status (Figures 5 and 6).  For the ER positive subgroup 
the primary finding remained, in that applying lower cutoffs of either 15 or 50 combined 
with a higher cutoff of 150 could separate strong and weak from moderate expression, 
where moderate expression was associated with longer overall survival.  However, in the ER 
negative subgroup it was not possible to identify a moderate subgroup for which prognosis 
was more favorable.  Instead, any single cutoff between 12 and 270 led to a significant 
stratification for which high p53 expression correlated with better overall survival, relative 
to the other patients within the ER negative subgroup.  This is consistent with reports from 
the IBCSG Trials VIII and IX, where high p53 was also found to be associated with better 
survival among ER negative patients, but worse survival among ER positive patients28. 
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For Ki67, the result was similar.  For ER positive cases, use of the same cutoff thresholds as 
applied to the whole dataset identified an association between higher Ki67 labelling indices 
and worse overall survival, which was statistically significant for the Confirm antibody (p = 
0.0039, cutoff 25) and not quite significant for MM1 (p = 0.0547, cutoff 15).  However, 
within the ER negative subgroup the trend was reversed for both antibodies: higher Ki67 
indices were associated with improved survival.  This finding was statistically significant for 
both antibodies using similar cutoff thresholds (cutoff 35, p = 0.0176 Confirm antibody; 
cutoff 30, p = 0.0364 MM1).  A significant association of higher Ki67 indices with improved 
prognosis was not evident within the pathologist’s manual scores.  
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Discussion 
In this study, we have shown the ability of DIA to accurately score a range of important 
biomarkers in breast cancer TMAs.  Using the QuPath digital pathology platform we were 
able to identify associations between biomarker expression and overall survival with a 
similar or better level of statistical significance to that achieved through manual scoring by 
an experienced pathologist, while also uncovering additional insights that warrant further 
investigation and validation.  Importantly, all of this has been achieved using automated 
tumor recognition algorithms that can be quickly and interactively trained to distinguish 
between different cell types.  
 
Several commercial digital pathology solutions, such as Halo (Indica Labs, New Mexico, 
USA), Tissue Studio (Definiens AG, Munich, Germany) or Oncotopix (Visiopharm A/S, 
Hoersholm, Denmark), also provide TMA biomarker evaluation capabilities.  Typically, the 
approach implemented in software applications such as these is to first identify regions of 
interest (e.g. areas of tumor) based on an automated or semi-automated region 
identification using texture and color features, or alternatively by aligning a tumor mask 
derived from an adjacent tissue section stained with a cytokeratin marker.  Cells within 
these regions are then segmented and scored according to staining intensity to produce the 
final result.  While QuPath offers some limited texture-based region identification, it 
currently does not provide image registration capabilities to align tissue sections 
automatically.  Rather, the preferred approach within QuPath switches the order of 
operations, so that cell segmentation is placed first and then followed by a machine learning 
classification step to identified the subpopulation of cells to be scored.  In practice, this 
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means that all cells may be segmented up-front by batch processing, after which a classifier 
to distinguish between cell types can be either loaded from disk and applied, or trained 
interactively based upon annotations provided by the user containing examples of different 
cell types (Supplementary Figure 1).  In both cases the final results are available 
immediately after classification. 
 
The ability to perform algorithm training and verification of the results across a cohort in 
one sitting helps ensure an effective use of a pathologist’s time.  During interactive training, 
the classification tends to stabilize quickly for common cell patterns, but an experienced 
pathologist browsing the slides may recognize examples of cells that differ markedly from 
those previously seen and have been misclassified; in such cases they may add new 
annotations to address the problem immediately and generate an improved set of results – 
without a need to repeat lengthy processing steps.  This approach also avoids a reliance on 
cytokeratin staining, which substantially increases cost and laboratory effort, and limits the 
analysis to the intersection of tissue samples where both the biomarker of interest and 
cytokeratin staining has been successfully applied.  On the other hand, the method of 
analysis described here is subject to the effectiveness of cell identification and classification, 
which may vary depending upon the stain quality and biomarker expression pattern.  In 
particular, cell classification methods based on morphological or texture features may 
perform less robustly on lower grade tumors, where the features upon which the 
classification is based may vary less between tumor and benign cells.  To this end, critical 
evaluation of the results and stringent quality control at all stages are essential to ensure 
the accuracy of the results, irrespective of the DIA software and approach used. 
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Related to the above, we also explored the issues involved when assessing the performance 
of DIA for biomarker scoring.  We have focused on two separate measures of success: 
agreement with manual scoring by a trained pathologist, and the ability to explore 
statistically the relevance of marker stratification of patients by survival analysis.  Neither 
measure alone is scientifically optimal.  Considering manual scoring methods to be the gold 
standard fails to take into account that DIA may be capable of improved accuracy over that 
of a human. Also, demonstrating improved statistical significance in patient stratification 
may be a reflection on cohort size, patient event proportions and other factors indicating 
overfitting, and does not necessarily result in cutoff thresholds that are either generalizable 
or transferable to clinical practice.  Furthermore, in the case of ER and PR, we have shown 
that the association with survival is sufficiently strong such that there is a considerable 
‘margin for error’ in scoring when this is used to define successful analysis; so much so that 
including a large number of non-tumor cells in the evaluation, while somewhat diluting the 
robustness, can still lead to a highly significant result and excellent agreement with 
dichotomized manual scores.  This ought to serve as a warning against using ER and PR 
alone as a demonstration that a new method of analysis is fit-for-purpose in a general 
setting for other biomarkers.  For these reasons, we have presented our results across a 
range of different biomarkers, both from multiple viewpoints and with multiple different 
methods of cutoff selection, as a measure of the robustness of our analysis. 
 
Our results also revealed two results of biological interest.  The distinction between weak 
staining for p53 and no measurable expression was made by our group in a qualitative 
fashion after careful validation of the p53 IHC8, demonstrating the different mutation status 
associated to this pattern. For the first time to our knowledge, this is now reproduced using 
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DIA from standard brightfield IHC staining. The importance of this finding requires a 
subsequent, independent cohort; however, this observation highlights the potential of DIA 
in generating results with a broader genomic relevance.  
 
Additionally, our initial results showed the strong dependence of Ki67 scoring on the specific 
antibody used, in keeping with previous reports9.  However, by separately analyzing ER-
positive and ER-negative patients, we further demonstrated that substantial differences in 
the interpretation of Ki67 existed for this cohort.  These results are perhaps surprising, given 
that it is well established that a high Ki67 labelling index is associated with worse 
prognosis16.  Nevertheless, it is also known that Ki67 score can be predictive of neoadjuvant 
chemotherapy response29, and mean Ki67 labelling indices have been found to be higher in 
patients with a pathological complete response after neoadjuvant chemotherapy; this has 
led to the hypothesis that there may be a high cutoff above which prognosis is better than 
in patients with lower Ki67 values30.  Since all patients within the cohort in this study 
received anthracycline-based chemotherapy8, our findings that high Ki67 values within the 
ER-negative subgroup are significantly associated with better overall survival lends tentative 
support to this hypothesis, and warrants further investigation.  In any case, the fact that the 
‘correct’ interpretation of Ki67 may take on opposing roles depending upon the treatment 
and molecular subtype of the cancer may shed some further light on why it has proven so 
difficult to establish a standardized approach to Ki67 evaluation with a single accepted 
methodology and cutoff value16,24, since the best cutoff found within each study is highly 
dependent upon the makeup of the cohort.  Our comparison of two antibodies against Ki67 
has also reiterated the importance of antibody selection.   
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Based upon all our results, we are able to draw some conclusions regarding the application 
of DIA to biomarker evaluation.  Firstly, we have shown that it is possible to robustly score a 
range of biomarkers in TMAs without a need for a tumor identification marker.  Secondly, 
we have demonstrated that tumor identification may not be essential in all cases whenever 
the goal is simply to ascertain an association between the biomarker and survival within 
TMAs; however, where it is applied, tumor recognition improves the robustness of the 
scoring by removing one confounding factor.  Furthermore, for some biomarkers it can be 
particularly important that the correct cells are being scored in order to identify subtle 
effects.  Thirdly, we have shown the benefits of using scoring metrics for DIA with a high 
dynamic range.  This improves the ability to distinguish between more subtle differences, 
while also increasing the tolerance to a small number of artifacts or misclassifications.  The 
H-score meets this criterion but the Allred score does not.  Thus, it should be kept in mind 
when planning DIA studies that the preferred method of scoring may well differ from that 
which would be used by a pathologist scoring manually. 
 
Supplementary information is available at Laboratory Investigation’s website. 
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Figure legends 
 
Figure 1 
Example images showing QuPath’s trained tumor recognition applied to TMA cores stained 
for PR, Ki67 (Confirm) and HER2.  Detected cells are color-coded according to their 
classification: red (tumor, strongly-positive), orange (tumor, moderately-positive), yellow 
(tumor, weakly-positive), blue (tumor, negative) and green (non-tumor). 
 
Figure 2: 
Kaplan Meier curves showing 5-year overall survival based on patient stratification using DIA 
scoring with manually-defined cutoff thresholds (see Table 2). 
 
Figure 3: 
Distribution of p-values for all possible thresholds represented in the data for image analysis 
scoring of each biomarker.  Horizontal (dotted) line indicates threshold for significance at 
0.05 level. 
 
Figure 4: 
Application of additional cutoffs to p53 data.  (Left, center) Cutoffs to separate weak from 
moderate staining are set at H-scores of 15 and 50 respectively; cases exhibiting strong 
staining (H-score > 150) are excluded (n = 179).  (Right) Three cutoffs (15, 50 and 150) are 
applied to stratify patients in the full dataset. 
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Figure 5: 
(Top) Kaplan Meier curves showing 5-year overall survival when stratifying patients 
according to p53 IHC scores, after separating patients according to ER status.  Cutoffs used 
are 15 and 150 (ER-positive; n = 168, p-value compares extreme low and high vs moderate) 
and 50 only (ER-negative; n = 112).  (Bottom) Plots showing how p-values vary according to 
different cutoff thresholds that could be applied for patient stratification (log-rank test). 
 
Figure 6: 
Kaplan Meier curves showing 5-year overall survival when stratifying patients according to 
Ki67 labelling indices determined by DIA, after separating patients according to ER status. 
 






 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Comparison of pathologist and DIA scores for each biomarker set. 
Pearson’s and Spearman’s correlation coefficients are calculated based on matched ‘raw’ scores.  AUC 
refers to the area under the Receiver Operating Characteristic curve, where DIA scores are compared with 
thresholded pathologist scores as ‘ground truth’. Note that DIA scores using the Confirm antibody against 
Ki67 are compared with the pathologist’s Ki67 scores, which were made using the MM1 antibody only. 
Because of the requirement for two cutoffs, no AUC is available for p53. 
 
 N PCC Rho AUC 
ER 267 0.908 0.892 0.996 
PR 277 0.862 0.887 0.978 
HER2 278 0.886 0.843 0.949 
Ki67 MM1 270 0.852 0.795 0.900 
Ki67 Confirm 260 0.771 0.729 0.877 
p53 279 0.926 0.888 - 
 
 N Cutoff method Cutoff ≥ Total (high/low) 
Observed 
(high/low) 
Log-rank 
P-value 
ER 
Pathologist 288 Manual  174/114 17/24 0.00297 
QuPath 268 Manual 5 177/91 16/20 0.00132 
QuPath 268 Median 126.46 134/134 10/26 0.00187 
QuPath 268 Log-rank 172.94 117/151 5/31 0.00007 
(0.00254)
PR 
Pathologist 286 Manual  135/151 9/33 0.00014 
QuPath 279 Manual 5 145/134 11/28 0.00068 
QuPath 279 Median 7.93 140/139 10/29 0.00055 
QuPath 279 Log-rank 66.24 98/181 3/36 0.00010 
(0.00360)
HER-2 
Pathologist 284 Manual 71/213 17/23 0.00582 
QuPath 279 Manual 1 63/216 15/24 0.00897 
QuPath 279 Median 0 279/0 39/0 - 
QuPath 279 Log-rank 25.62 62/217 15/24 0.00703 
(0.12337)
Ki67 (MM1) 
Pathologist 282 Manual  135/147 25/14 0.01611 
QuPath 274 Manual 15 113/161 19/20 0.23864 
QuPath 274 Median 11.89 137/137 21/18 0.53721 
QuPath 274 Log-rank 2.46 233/41 30/9 0.12625 
(0.80083)
Ki67 (CONFIRM, 30-9 clone) 
QuPath 267 Manual 25.00 125/142 25/14 0.01300 
QuPath 267 Median 24.10 134/133 28/11 0.00238 
QuPath 267 Log-rank 24.55 130/137 28/11 0.00114 
(0.02840)
p53 
Pathologist 287 Manual  92/111/84 17/9/15 0.01649 
QuPath 280 Manual 40/180 91/92/97 16/5/19 0.00358 
QuPath 280 Tertiles 34.61/174.1 93/93/94 16/7/17 0.02410 
QuPath 280 Log-rank 13.19/185.1 89/143/48 16/11/13 0.00090 
 
 
Table 2: Survival analysis based on thresholding both manual and image analysis biomarker scores. 
Where a single cutoff threshold was determined by minimizing the log-rank p-value, adjusted values are 
also shown in parentheses. In the case of p53, where two thresholds are required, total and observed 
patient numbers are shown according to high/moderate/low biomarker scores. 
 
 
 
 N Cutoff ≥ Sensitivity Specificity Accuracy Kappa P-value 
ER 
Tumor H-score 267 16 0.975 0.952 0.966 0.929 0.0049
All cells H-score 267 13 0.957 0.952 0.955 0.906 0.0025
Tumor Allred score 267 4 0.759 0.971 0.843 0.689 0.0079
PR 
Tumor H-score 277 8 0.954 0.911 0.931 0.863 0.0002
All cells H-score 277 10 0.908 0.959 0.935 0.869 0.0018
Tumor Allred score 277 4 0.748 0.932 0.845 0.686 0.0030
HER-2 
Tumor HER2 H-score 278 1 0.899 0.995 0.971 0.921 0.0090
All cells HER2 H-score 278 1 0.812 0.995 0.950 0.857 0.0070
Ki67 (MM1) 
Tumor Positive % 270 10 0.908 0.770 0.837 0.675 0.8689
All cells Positive % 270 8 0.863 0.827 0.844 0.689 0.3587
Ki67 (CONFIRM, 30-9 clone) 
Tumor Positive % 260 24 0.828 0.783 0.804 0.608 0.0028
All cells Positive % 260 14 0.820 0.790 0.804 0.608 0.0137
p53 
Tumor H-score 279 14/190 0.726 0.910 0.799 0.603 0.0046
All cells H-score 279 15/121 0.536 0.919 0.688 0.411 0.1487
Tumor Allred score 279 4/7 0.827 0.730 0.789 0.558 0.0383
 
 
Table 3: Comparison of different scoring metrics. 
A cutoff threshold is determined automatically in each case by correlating DIA scores with a pathologist’s 
(binary) clinical scores, and this used to determine sensitivity, specificity, accuracy and Cohen’s kappa 
values.  A log-rank test is also applied with the identified cutoff to determine statistical significance for 5-
year overall survival. 
